NanoEnTek reported cumulative consolidated revenue of KRW 33.5 billion for the first three quarters of this year, up 31.4% from the same period last year.


NanoEnTek Posts KRW 33.5 Billion in Cumulative Q3 Revenue... "Ramps Up Global Market Push" View original image

According to NanoEnTek on November 17, operating profit for the same period was KRW 610 million, continuing its growth trend. In particular, cumulative third-quarter revenue from FREND, the company’s in vitro diagnostic device product line, reached KRW 10.1 billion, up 15.6% from the same period last year.


NanoEnTek plans to expand its presence in global markets, focusing on its wellness and longevity businesses. In November, its wellness business will introduce three diagnostic products related to women's health in the U.S. market: estradiol, follicle-stimulating hormone (FSH), and thyroid hormone (Free T3). Based on its point-of-care testing platform, FREND, the products can provide quantitative test results quickly using a small blood sample. The company plans to expand into women's health by leveraging the sales network it has established in the U.S. men's health clinic market.


In its longevity business, NanoEnTek is continuing its partnership with L'Oréal, focusing on Cell BioPrint, a skin analysis device co-developed with the company and first unveiled at CES 2025. Through this collaboration, NanoEnTek plans to apply its precision diagnostic technology to personalized skincare and further strengthen the commercial foundation of its longevity business.



A NanoEnTek official said, "The global healthcare industry is shifting beyond disease diagnosis and treatment toward prevention and personalized health management. Building on its precision diagnostic technology, NanoEnTek is actively seeking business opportunities in high-growth fields such as women's health, wellness, and longevity."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing